Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$7.50M
EBITDA Margin
-3822.36%
TTM Avg
-2499.82%
3Y Avg
-7123.25%
5Y Avg
-7123.25%
Market Cap
$7.45M
EBITDA Margin
1.07%
TTM Avg
13.21%
3Y Avg
13.21%
5Y Avg
13.21%
Market Cap
$7.72M
EBITDA Margin
-144973.96%
TTM Avg
-73136.05%
3Y Avg
-36678.29%
5Y Avg
-29395.87%
Market Cap
$7.25M
EBITDA Margin
-0.29%
TTM Avg
-74.83%
3Y Avg
-125.41%
5Y Avg
-344.12%
Market Cap
$7.24M
EBITDA Margin
-1839.87%
TTM Avg
-1245.27%
3Y Avg
-1681.64%
5Y Avg
-1341.06%
Market Cap
$7.95M
EBITDA Margin
-951.52%
TTM Avg
-1801.56%
3Y Avg
-1801.56%
5Y Avg
-1801.56%
Market Cap
$7.92M
EBITDA Margin
-638.49%
TTM Avg
-11234.29%
3Y Avg
-10030.31%
5Y Avg
-9704.67%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | $7.57M | N/A | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.50M | -3822.36% | -2499.82% | -7123.25% | -7123.25% |
| Skye Bioscience, Inc. (SKYE)vs › | $7.45M | 1.07% | 13.21% | 13.21% | 13.21% |
| ENDRA Life Sciences Inc. (NDRA)vs › | $7.72M | -144973.96% | -73136.05% | -36678.29% | -29395.87% |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.25M | -0.29% | -74.83% | -125.41% | -344.12% |
| Longeveron Inc. (LGVN)vs › | $7.24M | -1839.87% | -1245.27% | -1681.64% | -1341.06% |
| Aprea Therapeutics, Inc. (APRE)vs › | $7.95M | -951.52% | -1801.56% | -1801.56% | -1801.56% |
| Traws Pharma, Inc. (TRAW)vs › | $7.92M | -638.49% | -11234.29% | -10030.31% | -9704.67% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.95M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.91M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
